Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTCs and EGFR pathway study for cetuximab efficacy prediction in advanced head and neck squamous cell carcinoma
ChiCTR1800015844Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Hematology and Radiological examination. Started Jun 2018; status: recruiting.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR1800015844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015844.